Monica Wallter
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 737 070922
Email: monica.wallter@liddspharma.com
Bengt Norvik
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 730 746800
Email: bengt.norvik@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2019-03-18
LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020 - 2019-03-13 LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
- 2019-03-12 LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris
- 2019-03-12 LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
